Tuesday, October 13, 2026

Less Than Hour Before The NASDAQ Open, MicroVision Is Up By 4%

Less Than  Hour Before The NASDAQ Open, MicroVision Is Up By 4%

(VIANEWS) - The NASDAQ opens in less than hour and MicroVision's pre-market value is already 4.95% up.

MicroVision's last close was $1.82, 69.46% below its 52-week high of $5.96.

The last session, NASDAQ finished with MicroVision (MVIS) dropping 7.14% to $1.82. NASDAQ slid 1.98% to $11,799.16, after two sequential sessions in a row of losses, on what was an all-around bearish trend exchanging session.

About MicroVision

MicroVision, Inc. develops and sells lidar sensors used in automotive safety and autonomous driving applications. Its laser beam scanning technology is based on micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company also develops micro-display concepts and designs for head-mounted augmented reality (AR) headsets, as well as 1440i MEMS module supporting AR headsets; interactive display solutions for the smart speakers market; and Consumer Lidar used in smart home systems. In addition, it develops 1st Generation LRL module. The company sells its products primarily to original equipment manufacturers and original design manufacturers. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.

Earnings Per Share

As for profitability, MicroVision has a trailing twelve months EPS of $-0.32.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -52.44%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

MicroVision's EBITDA is -22.97.

Volume

Today's last reported volume for MicroVision is 2404481 which is 1.5% above its average volume of 2237840.

Moving Average

MicroVision's worth is way below its 50-day moving average of $2.41 and way below its 200-day moving average of $3.37.

Revenue Growth

Year-on-year quarterly revenue growth declined by 100%, now sitting on 664k for the twelve trailing months.

More news about MicroVision (MVIS).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com